日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Sanofi targets ground-breaking therapies with a new R&D strategy

chinadaily.com.cn | Updated: 2022-03-31 11:04
Share
Share - WeChat
John Reed, executive vice-president, global head of research and development at Sanofi. [Photo provided to chinadaily.com.cn]

"We are sharpening our R&D focus on first-in-class or best-in-class medicines and vaccines in order to address the world's most urgent healthcare needs", said John Reed, executive vice-president and head of Global R&D of Sanofi. He emphasized Sanofi's scientific mission when talking about the company's R&D strategy, "because patients are counting on us."

Reed, formerly the head of Roche Pharma Research and Early Development (pRED), joined Sanofi in 2018, where he participated in and witnessed a crucial strategic transformation of the company.

As an essential step in Sanofi's "Play to Win" strategy, announced in 2019, the company launched a new brand identity and purpose to highlight its corporate mission "Chase the miracles of science to improve people's lives" early this year.

Companies that implement rebranding will often make key strategic adjustments, and Sanofi is no exception. As an R&D-driven pharmaceutical company, Sanofi has made the transformation of its R&D strategy central to its rebranding initiatives.

"The pursuit of scientific miracles is a dynamic process, and the process of R&D is challenging, but we don't let the setbacks deter us from pushing forward and working to improve the lives of patients," Reed said.

A new transformation, a new ambition

Founded in 1973, Sanofi is a young global pharmaceutical company. In the past several decades, it has developed many breakthrough therapies, including Lantus (insulin glargine), Taxotere (anti-cancer drug), Lovenox (anti-coagulant), Aubagio (multiple sclerosis), and Cerezyme (Gaucher disease).

For almost half a century, Sanofi has been protecting lives with its vaccines, saving and transforming lives with its cutting-edge science, from primary care to the treatment of cancer and rare diseases. It took Sanofi only 32 years to go from being a small company to being one of the top pharmaceutical giants in the world, an astonishingly rapid ascent compared with century-old pharmaceutical companies.

Despite such extraordinary past achievements, Sanofi is reflecting on the most urgent healthcare needs which have yet to be resolved. Can innovation and R&D be refocused? Can products have greater clinical value? How to sustain long-term growth? According to Reed, Sanofi has strictly prioritized and reallocated resources for R&D.

Based on its expertise and experience with preventing and treating conditions from chronic diseases to rare diseases, Sanofi further optimizes resources to sharpen its R&D focus to first-in-class or best-in-class programs in vaccines and specialty care areas like immunology and oncology, where recent breakthroughs open up a world of new therapeutic opportunities.

A sign of Sanofi's progress is that in 2021 it added 36 phase I and phase II clinical development programs, a clear indication of its strong pipeline of early-stage projects. The company is also investing more in biologics – seen in the fact that they now represent over 70 percent of its pipeline.

According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.

Sanofi's changes are also evident in its financial performance. In the newly released 2021 annual financial report, specialty medicine has become Sanofi's most prominent business unit by sales for the first time, with R&D investment in specialty drug products accounting for 95 percent of the company's total R&D investment, up by about 50 percent from that of 2017.

1 2 3 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产精品13页| 国精品人妻无码一区二区三区性色 | 在线观看www | 精品福利在线视频 | 亚洲第一黄色网 | 久久久成人精品视频 | 亚洲国产aⅴ成人精品无吗 国内成人自拍视频 | 国产亚洲精品精品国产亚洲综合 | 欧美性视频网 | 九九99热久久精品在线9 | 国产精品久久国产精品久久 | 一区二区三区视频免费 | 亚洲视频区 | 日韩a无v码在线播放免费 | 激情网五月天 | 日本黄色大片免费看 | 中文字幕国产 | 日韩精品欧美一区二区三区 | 国产成人精品一区在线播放 | 日韩欧美一区二区三区不卡 | 欧美日韩一区二区综合在线视频 | 日本午夜在线观看 | 欧美性一区二区三区 | 成年人免费小视频 | 91传媒蜜桃香蕉在线观看 | 亚洲在线视频网站 | 啪啪网免费 | 国内精品视频免费观看 | av中文字幕在线 | 亚洲国产中文字幕在线观看 | 日本人麻豆 | 九九热视频这里只有精品 | 色欲天天婬色婬香视频综合网 | 岛国av在线 | av中文字幕在线 | 孕妇体内谢精满日本电影 | 欧美另类视频一区二区三区 | 午夜精品久久久久久久99蜜桃i | a视频在线| 王的女人印度剧电视剧免费观看32集 | 一区二区三区av |